Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Chronic Heart Failure

  Free Subscription


Articles published in Cardiovasc Res

Retrieve available abstracts of 59 articles:
HTML format



Single Articles


    October 2021
  1. SANTEMA BT, Arita VA, Sama IE, Kloosterman M, et al
    Pathophysiological pathways in patients with heart failure and atrial fibrillation.
    Cardiovasc Res. 2021 Oct 23. pii: 6409189. doi: 10.1093.
    PubMed     Abstract available


  2. MOHAISSEN T, Proniewski B, Targosz-Korecka M, Bar A, et al
    Temporal relationship between systemic endothelial dysfunction and alterations in erythrocyte function in a murine model of chronic heart failure.
    Cardiovasc Res. 2021 Oct 7. pii: 6383136. doi: 10.1093.
    PubMed     Abstract available


    August 2021
  3. DAVIDSON SM, Padro T, Bollini S, Vilahur G, et al
    Progress in cardiac research: from rebooting cardiac regeneration to a complete cell atlas of the heart.
    Cardiovasc Res. 2021;117:2161-2174.
    PubMed     Abstract available


  4. RICHARDS AM
    Proteomic probing for markers and mechanisms in Heart Failure.
    Cardiovasc Res. 2021 Aug 10. pii: 6347578. doi: 10.1093.
    PubMed    


    July 2021
  5. ZHAO B, Bouchareb R, Lebeche D
    Resistin deletion protects against heart failure injury by targeting DNA damage response.
    Cardiovasc Res. 2021 Jul 29. pii: 6330773. doi: 10.1093.
    PubMed     Abstract available


  6. ABDELLATIF M, Lam CSP
    Scientists on the Spot: A fraction of wisdom on heart failure.
    Cardiovasc Res. 2021;117:e114-e115.
    PubMed    


  7. MARKOUSIS-MAVROGENIS G, Tromp J, Ouwerkerk W, Fereirra JP, et al
    Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF.
    Cardiovasc Res. 2021 Jul 15. pii: 6321950. doi: 10.1093.
    PubMed     Abstract available


  8. DIEZ J, de Boer RA
    Management of cardiac fibrosis is the largest unmet medical need in heart failure Cardiac fibrosis in heart failure.
    Cardiovasc Res. 2021 Jul 9. pii: 6318397. doi: 10.1093.
    PubMed     Abstract available


  9. GRASSI G, Mancia G, Esler M
    CENTRAL AND PERIPHERAL SYMPATHETIC ACTIVATION IN HEART FAILURE.
    Cardiovasc Res. 2021 Jul 7. pii: 6317668. doi: 10.1093.
    PubMed     Abstract available


    June 2021
  10. ONODI Z, Ruppert M, Kucsera D, Sayour AA, et al
    AIM2-driven inflammasome activation in heart failure.
    Cardiovasc Res. 2021 Jun 12. pii: 6297397. doi: 10.1093.
    PubMed     Abstract available


  11. SANSONETTI M, De Windt LJ
    Non-coding RNAs in cardiac inflammation: key drivers in the pathophysiology of heart failure.
    Cardiovasc Res. 2021 Jun 7. pii: 6294284. doi: 10.1093.
    PubMed     Abstract available


  12. NAUMENKO N, Mutikainen M, Holappa L, Ruas JL, et al
    PGC-1alpha deficiency reveals sex-specific links between cardiac energy metabolism and EC-coupling during development of heart failure in mice.
    Cardiovasc Res. 2021 Jun 4. pii: 6292089. doi: 10.1093.
    PubMed     Abstract available


    May 2021

  13. Corrigendum to: Heart failure or heart success?
    Cardiovasc Res. 2021 May 18. pii: 6277376. doi: 10.1093.
    PubMed    


    April 2021

  14. Retraction: Influence of p53 in the transition of myotrophin-induced cardiac hypertrophy to heart failure.
    Cardiovasc Res. 2021 Apr 22. pii: 6245632. doi: 10.1093.
    PubMed    


  15. BOLLI R, Solankhi M, Tang XL, Kahlon A, et al
    Cell Therapy in Patients with Heart Failure: A Comprehensive Review and Emerging Concepts.
    Cardiovasc Res. 2021 Apr 19. pii: 6237881. doi: 10.1093.
    PubMed     Abstract available


    March 2021
  16. KARWI QG, Ho KL, Pherwani S, Ketema EB, et al
    Concurrent diabetes and heart failure: interplay and novel therapeutic approaches.
    Cardiovasc Res. 2021 Mar 30. pii: 6203809. doi: 10.1093.
    PubMed     Abstract available


  17. SELVARAJ S, Margulies KB
    Exogenous ketones in the healthy heart: the plot thickens.
    Cardiovasc Res. 2021;117:995-996.
    PubMed    


  18. TAKAHARA S, Soni S, Maayah ZH, Ferdaoussi M, et al
    Ketone Therapy for Heart Failure: Current Evidence for Clinical Use.
    Cardiovasc Res. 2021 Mar 10. pii: 6168424. doi: 10.1093.
    PubMed     Abstract available


  19. CUOMO A, Pirozzi F, Tocchetti CG
    Low-intensity pulsed ultrasound (LIPUS) in heart failure with preserved ejection fraction (HFpEF): lupus in fabula?
    Cardiovasc Res. 2021 Mar 5. pii: 6159769. doi: 10.1093.
    PubMed    


    February 2021
  20. LUXAN G, Dimmeler S
    The vasculature: a therapeutic target in heart failure?
    Cardiovasc Res. 2021 Feb 23. pii: 6146925. doi: 10.1093.
    PubMed     Abstract available


  21. TERAMOTO K, Tromp J, Lam CSP
    Heart failure or heart success?
    Cardiovasc Res. 2021 Feb 13. pii: 6134544. doi: 10.1093.
    PubMed    


  22. DE LUCIA C, Grisanti LA, Borghetti G, Piedepalumbo M, et al
    GRK5 contributes to impaired cardiac function and immune cell recruitment in post-ischemic heart failure.
    Cardiovasc Res. 2021 Feb 9. pii: 6131786. doi: 10.1093.
    PubMed     Abstract available


    January 2021
  23. HEGYI B, Ko CY, Bossuyt J, Bers DM, et al
    Two-hit mechanism of cardiac arrhythmias in diabetic hyperglycemia: reduced repolarization reserve, neurohormonal stimulation and heart failure exacerbate susceptibility.
    Cardiovasc Res. 2021 Jan 23. pii: 6105172. doi: 10.1093.
    PubMed     Abstract available


  24. CICCARELLI M, Dawson D, Falcao-Pires I, Giacca M, et al
    Reciprocal organ interactions during heart failure-a position paper from the ESC working group on myocardial function.
    Cardiovasc Res. 2021 Jan 22. pii: 6105178. doi: 10.1093.
    PubMed     Abstract available


  25. TOENNIS T, Kirchhof P
    Connecting the dots? Rate control, heart failure, and atrial fibrillation.
    Cardiovasc Res. 2021;117:336-337.
    PubMed    


  26. PANENI F, Sciarretta S, Costantino S
    Tackling myocardial oxidative stress with empagliflozin: are we big enough to fight heart failure with preserved ejection fraction?
    Cardiovasc Res. 2021;117:343-345.
    PubMed    


  27. LIMA CORREA B, El Harane N, Gomez I, Rachid Hocine H, et al
    Extracellular vesicles from human cardiovascular progenitors trigger a reparative immune response in infarcted hearts.
    Cardiovasc Res. 2021;117:292-307.
    PubMed     Abstract available


    November 2020
  28. MELI AC, Fischmeister R
    Scientists on the spot: Phosphodiesterases and heart failure.
    Cardiovasc Res. 2020 Nov 1. pii: 5952729. doi: 10.1093.
    PubMed    


    October 2020
  29. NAKAMURA M, Odanovic N, Nakada Y, Dohi S, et al
    Dietary Carbohydrates Restriction Inhibits The Development Of Cardiac Hypertrophy And Heart Failure.
    Cardiovasc Res. 2020 Oct 18. pii: 5929700. doi: 10.1093.
    PubMed     Abstract available


  30. PANICO C, Kallikourdis M, Condorelli G
    Defining circulating mononuclear cells in heart failure through single-cell RNA sequencing: new insights for an old disease.
    Cardiovasc Res. 2020 Oct 13. pii: 5922371. doi: 10.1093.
    PubMed    


  31. LANG NN, Dobbin SJH, Petrie MC
    Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial.
    Cardiovasc Res. 2020;116:e152-e155.
    PubMed    


    September 2020
  32. WITHAAR C, Meems LMG, Markousis-Mavrogenis G, Boogerd CJ, et al
    The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of Heart Failure with Preserved Ejection Fraction.
    Cardiovasc Res. 2020 Sep 1. pii: 5900261. doi: 10.1093.
    PubMed     Abstract available


    August 2020
  33. PERROTTA S, Carnevale D
    A neuro-humoral activation of RAAS in endothelial dysfunction modulating immunity in heart failure.
    Cardiovasc Res. 2020 Aug 4. pii: 5880579. doi: 10.1093.
    PubMed    


  34. BERTERO E, Stork S, Maack C
    REPORT-HF reveals global inequalities in health care provision and prognosis of patients with acute heart failure.
    Cardiovasc Res. 2020;116:e112-e114.
    PubMed    


    July 2020
  35. NAGUEH SF
    Heart Failure with Preserved Ejection Fraction: Insights into Diagnosis and Pathophysiology.
    Cardiovasc Res. 2020 Jul 27. pii: 5876832. doi: 10.1093.
    PubMed     Abstract available


  36. SCHIATTARELLA GG, Rodolico D, Hill JA
    Metabolic Inflammation in Heart Failure with Preserved Ejection Fraction.
    Cardiovasc Res. 2020 Jul 14. pii: 5871499. doi: 10.1093.
    PubMed     Abstract available


  37. MELI AC, de Tombe P
    Scientists on the Spot: Myocardium and myofilaments.
    Cardiovasc Res. 2020;116:e96-e97.
    PubMed    


    May 2020
  38. KOLIJN D, Pabel S, Tian Y, Lodi M, et al
    Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Galpha oxidation.
    Cardiovasc Res. 2020 May 12. pii: 5836298. doi: 10.1093.
    PubMed     Abstract available


    April 2020
  39. ABPLANALP WT, John D, Cremer S, Assmus B, et al
    Single cell RNA sequencing reveals profound changes in circulating immune cells in patients with heart failure.
    Cardiovasc Res. 2020 Apr 20. pii: 5822866. doi: 10.1093.
    PubMed     Abstract available


  40. PACKER M
    Critical Examination of Mechanisms Underlying the Reduction in Heart Failure Events With SGLT2 Inhibitors: Identification of a Molecular Link Between Their Actions to Stimulate Erythrocytosis and to Alleviate Cellular Stress.
    Cardiovasc Res. 2020 Apr 3. pii: 5815560. doi: 10.1093.
    PubMed     Abstract available


    March 2020
  41. RADEMAKER MT, Scott NJA, Koh CY, Kini RM, et al
    Natriuretic peptide analogues with distinct vasodilatory or renal activity: Integrated effects in health and experimental heart failure.
    Cardiovasc Res. 2020 Mar 13. pii: 5804984. doi: 10.1093.
    PubMed     Abstract available


  42. VAN BERLO JH, Garry DJ
    Hearts and Hands: the good, the bad, and the ugly.
    Cardiovasc Res. 2020;116:470-472.
    PubMed    


  43. VOLLAND C, Schott P, Didie M, Manner J, et al
    Control of p21Cip by BRCA1-associated protein is critical for cardiomyocyte cell cycle progression and survival.
    Cardiovasc Res. 2020;116:592-604.
    PubMed     Abstract available


    February 2020
  44. MOLITOR M, Rudi WS, Garlapati V, Finger S, et al
    Nox2+ Myeloid cells drive vascular inflammation and endothelial dysfunction in heart failure after myocardial infarction via angiotensin II receptor type 1.
    Cardiovasc Res. 2020 Feb 20. pii: 5741408. doi: 10.1093.
    PubMed     Abstract available


    January 2020
  45. CAMICI PG, Tschope C, Carli MFD, Rimoldi O, et al
    Coronary microvascular dysfunction in hypertrophy and heart failure.
    Cardiovasc Res. 2020 Jan 30. pii: 5718012. doi: 10.1093.
    PubMed     Abstract available


  46. ZHANG D, Tu H, Wang C, Cao L, et al
    Inhibition of N-type calcium channels in cardiac sympathetic neurons attenuates ventricular arrhythmogenesis in heart failure.
    Cardiovasc Res. 2020 Jan 29. pii: 5717428. doi: 10.1093.
    PubMed     Abstract available


  47. VERMA S
    The DAPA-HF trial marks the beginning of a new era in the treatment of heart failure with reduced ejection fraction.
    Cardiovasc Res. 2020;116:e8-e10.
    PubMed    


  48. COHEN-SOLAL A, Logeart D
    Is the glass half full or half empty after PARAGON-HF?
    Cardiovasc Res. 2020;116:e5-e7.
    PubMed    


  49. CHEN MP, Kiduko SA, Saad NS, Canan BD, et al
    Stretching single titin molecules from failing human hearts reveals titin's role in blunting cardiac kinetic reserve.
    Cardiovasc Res. 2020;116:127-137.
    PubMed     Abstract available


    November 2019
  50. FILIPPATOS G, Farmakis D
    A look back: the quest for thrombosis in heart failure continues after COMMANDER HF.
    Cardiovasc Res. 2019;115:e140-e142.
    PubMed    


    October 2019
  51. SACK MN
    The Enigma of Anti-Inflammatory Therapy for the Management of Heart Failure.
    Cardiovasc Res. 2019 Oct 30. pii: 5610071. doi: 10.1093.
    PubMed    


  52. BILCHICK K, Kothari H, Narayan A, Garmey J, et al
    Cardiac resynchronization therapy reduces expression of inflammation-promoting genes related to interleukin-1beta in heart failure.
    Cardiovasc Res. 2019 Oct 15. pii: 5585796. doi: 10.1093.
    PubMed     Abstract available


  53. ANTONIADES C, Condorelli G
    Scientists on the Spot: non-coding RNAs and heart failure.
    Cardiovasc Res. 2019 Oct 9. pii: 5584268. doi: 10.1093.
    PubMed    


    March 2019
  54. DE KLEIJN DPV, Chong SY, Wang X, Yatim SMJM, et al
    Toll-like Receptor 7 Deficiency Promotes Survival and Reduces Adverse Left Ventricular Remodeling After Myocardial Infarction.
    Cardiovasc Res. 2019 Mar 4. pii: 5369232. doi: 10.1093.
    PubMed     Abstract available


    January 2019
  55. SINGH AP, Umbarkar P, Guo Y, Force T, et al
    Inhibition of GSK-3 to induce cardiomyocyte proliferation: a recipe for in situ cardiac regeneration.
    Cardiovasc Res. 2019;115:20-30.
    PubMed     Abstract available


  56. SURINKAEW S, Aflaki M, Takawale A, Chen Y, et al
    Exchange protein activated by cyclic-adenosine monophosphate (Epac) regulates atrial fibroblast function and controls cardiac remodelling.
    Cardiovasc Res. 2019;115:94-106.
    PubMed     Abstract available


  57. GRUND A, Szaroszyk M, Doppner JK, Malek Mohammadi M, et al
    A gene therapeutic approach to inhibit calcium and integrin binding protein 1 ameliorates maladaptive remodelling in pressure overload.
    Cardiovasc Res. 2019;115:71-82.
    PubMed     Abstract available


    December 2018
  58. MICKAEL C, Lee MH, Gu S, Graham BB, et al
    Comparing pulmonary hypertension severity between rat strains suggests right ventricle NK cells are protective.
    Cardiovasc Res. 2018 Dec 4. pii: 5229543. doi: 10.1093.
    PubMed    


    September 2018
  59. SCHLOSS MJ, Horckmans M, Guillamat-Prats R, Hering D, et al
    2-arachidonoylglycerol mobilizes myeloid cells and worsens heart function after acute myocardial infarction.
    Cardiovasc Res. 2018 Sep 28. pii: 5115994. doi: 10.1093.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: